Shares in Samsung BioLogics Co Ltd fell over 18 percent on Wednesday as South Korea’s watchdog Financial Supervisory Service provisionally decided it had breached accounting rules.


Shares in Samsung C&T Corp, which holds a 43 percent stake in drug contract manufacturer Samsung BioLogics, also fell more than 5 percent.


Samsung BioLogics said in a regulatory filing that it will prove it had engaged in proper accounting practices.